Provectus has announced that a second group of subjects has been treated in the company's Phase I clinical trial of PV-10 (Provecta) for ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer. Treatment with PV-10 was well tolerated by all
subjects, with no evidence of systemic or serious local side effects.
The
study consists of 20 subjects, and is being conducted at the Sydney Melanoma Unit
and the Newcastle Melanoma Unit, both located in New South Wales, Australia. Each
subject enrolled in the study has one or more tumors treated with a single injection
of PV-10 and the local response to the treatment is then observed for a period
of 12 to 24 weeks.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Stakeholders Urge Congress to Update Clinical Laboratory Diagnostics Legislation
The letter to lawmakers cites an urgent need to reform regulations covering laboratory developed tests and in vitro diagnostics.
Seniors Paying More for Generics Through Medicare Part D, Study Finds
The higher cost sharing did not correspond with an increase in the underlying price of generic drugs, Avalere said.